Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Aclacinomycin A
2. Nsc-208734
1. Aclacinomycin A
2. 57576-44-0
3. Aclarubicine
4. Aclarubicinum
5. Aclarubicina
6. Nsc-208734
7. Ma 144-a1
8. 74kxf8i502
9. Chebi:74619
10. Nsc 208734
11. Methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-4-(dimethylamino)-5-[(2s,4s,5s,6s)-4-hydroxy-6-methyl-5-[(2r,6s)-6-methyl-5-oxooxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate
12. Nsc208734
13. 1-naphthacenecarboxylic Acid,(2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-o-(2,6-dideoxy-4-o-((2r-trans)-tetrahydro-6-methyl-5-oxo-2h-pyran-2-yl)-alpha-l-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl)oxy)-, Methyl Ester, (1r-(1alpha,2beta,4beta))-
14. Antibiotic Ma144-a1
15. Aclacinomycin-a
16. Nsc240619
17. Methyl (1r,2r,4s)-4-((2r,4s,5s,6s)-4-(dimethylamino)-5-((2s,4s,5s,6s)-4-hydroxy-6-methyl-5-((2r,6s)-6-methyl-5-oxooxan-2-yl)oxyoxan-2-yl)oxy-6-methyloxan-2-yl)oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate
18. Acm-a
19. Refchem:915045
20. Glytoucan:g42541yc
21. L01db04
22. Ma144a1
23. G42541yc
24. Ma 144a1
25. Ma144-a1
26. (1r,2r,4s)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-o-(2,6-dideoxy-4-o-((2r,trans)-tetrahydro-6-methyl-5-oxo-2h-pyran-2-yl)-alpha-l-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl)oxy)-1-naphthacenecarboxylic Acid Methyl Ester
27. (1r,2r,4s)-4-((2r,4s,5s,6s)-4-(dimethylazaniumyl)-5-((2s,4s,5s,6s)-4-hydroxy-6-methyl-5-((2r,6s)-6-methyl-5-oxooxan-2-yl)oxyoxan-2-yl)oxy-6-methyloxan-2-yl)oxy-2-ethyl-2,7-dihydroxy-1-methoxycarbonyl-6,11-dioxo-3,4-dihydro-1h-tetracen-5-olate
28. 1-naphthacenecarboxylic Acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5, 7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-o-(2,6-dideoxy-4-o-((2r-trans)-tetrahydro-6-methyl-5-oxo-2h-pyran-2-yl)-alpha-l-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl)oxy)-, Methyl Ester,(1r-(1alpha,2beta,4beta))-
29. 260-824-3
30. Aclacur
31. Antibiotic Ma 144a1
32. Aclarubicino
33. Aclacinomycin A1
34. Methyl (1r,2r,4s)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-4-{[2,3,6-trideoxy-4-o-{2,6-dideoxy-4-o-[(2r,6s)-6-methyl-5-oxotetrahydro-2h-pyran-2-yl]-alpha-l-lyxo-hexopyranosyl}-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl]oxy}-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
35. Methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-4-(dimethylamino)-5-[(2s,4s,5s,6s)-4-hydroxy-6-methyl-5-[(2r,6s)-6-methyl-5-oxo-tetrahydropyran-2-yl]oxy-tetrahydropyran-2-yl]oxy-6-methyl-tetrahydropyran-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate
36. Antibiotic Ma 144a
37. Aclarubicine [inn-french]
38. Aclarubicinum [inn-latin]
39. Aclarubicino [inn-spanish]
40. Aclarubicins
41. C42h53no15
42. Unii-74kxf8i502
43. Aclarubicin [usan:inn:ban]
44. Ccris 2262
45. Mfcd00866250
46. Einecs 260-824-3
47. Spectrum_000467
48. Spectrum2_001934
49. Spectrum4_000768
50. Spectrum5_001041
51. Aclarubicin [inn]
52. Aclarubicin [jan]
53. Aclarubicin (usan/inn)
54. Aclarubicin [usan]
55. Aclacinomycin A (standard)
56. Schembl4532
57. Aclarubicin [mart.]
58. Aclacinomycin A [mi]
59. Aclarubicin [who-dd]
60. Kbiogr_001156
61. Kbioss_000947
62. Spbio_001967
63. Chembl502620
64. Orb2276869
65. Dtxsid1022554
66. Schembl29390785
67. Hy-n2306r
68. Kbio2_000947
69. Kbio2_003515
70. Kbio2_006083
71. Glxc-23058
72. Hms2089b13
73. Hy-n2306
74. Aw8655
75. Bdbm50368351
76. Ccg-39864
77. Aa08264
78. Db11617
79. Methyl (1r,2r,4s)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-o-(2,6-dideoxy-4-o-((2r,6s)-tetrahydro-6-methyl-5-oxo-2h-pyran-2-yl)-alpha-l-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl)oxy)-1-naphthacenecarboxylate
80. Cs-0020062
81. Ns00003246
82. C18638
83. D02756
84. Ab00052311-02
85. Q4674302
86. 1-naphthacenecarboxylic Acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-o-(2,6-dideoxy-4-o-((2r-trans)-tetrahydro-6-methyl-5-oxo-2h-pyran-2-yl)-alpha-l-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl)oxy)-, Methyl Ester, (1r-(1alpha,2beta,4beta))-
87. 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-o-[2,6-dideoxy-4-o-[(2r-trans)-tetrahydro-6-methyl-5-oxo-2h-pyran-2-yl]-.alpha.-l-lyxo-hexopyranosyl]-3-(dimethylamino)-.alpha.-l-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic Acid Methyl Ester
88. Methyl (1r,2r,4s)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-4-{[2,3,6-trideoxy-4-o-{2,6-dideoxy-4-o-[(2r,6s)-6-methyl-5-oxooxan-2-yl]-alpha-l-lyxo-hexopyranosyl}-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl]oxy}-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
| Molecular Weight | 811.9 g/mol |
|---|---|
| Molecular Formula | C42H53NO15 |
| XLogP3 | 3.8 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 16 |
| Rotatable Bond Count | 10 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 217 |
| Heavy Atom Count | 58 |
| Formal Charge | 0 |
| Complexity | 1530 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 13 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antibiotics, Antineoplastic
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
Topoisomerase II Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II.
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01D - Cytotoxic antibiotics and related substances
L01DB - Anthracyclines and related substances
L01DB04 - Aclarubicin
ATCvet Code
QL - Antineoplastic and immunomodulating agents
QL01 - Antineoplastic agents
QL01D - Cytotoxic antibiotics and related substances
QL01DB - Anthracyclines and related substances
QL01DB04 - Aclarubicin
ABOUT THIS PAGE
54
PharmaCompass offers a list of Aclarubicin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Aclarubicin manufacturer or Aclarubicin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Aclarubicin manufacturer or Aclarubicin supplier.
A Aclarubicin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aclarubicin, including repackagers and relabelers. The FDA regulates Aclarubicin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aclarubicin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Aclarubicin supplier is an individual or a company that provides Aclarubicin active pharmaceutical ingredient (API) or Aclarubicin finished formulations upon request. The Aclarubicin suppliers may include Aclarubicin API manufacturers, exporters, distributors and traders.
Aclarubicin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Aclarubicin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Aclarubicin GMP manufacturer or Aclarubicin GMP API supplier for your needs.
A Aclarubicin CoA (Certificate of Analysis) is a formal document that attests to Aclarubicin's compliance with Aclarubicin specifications and serves as a tool for batch-level quality control.
Aclarubicin CoA mostly includes findings from lab analyses of a specific batch. For each Aclarubicin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Aclarubicin may be tested according to a variety of international standards, such as European Pharmacopoeia (Aclarubicin EP), Aclarubicin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aclarubicin USP).
